Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report aims to provide a comprehensive presentation of the global market for Neuroblastoma Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroblastoma Treatment Drugs. This report contains market size and forecasts of Neuroblastoma Treatment Drugs in global, including the following market information:
Global Neuroblastoma Treatment Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Neuroblastoma Treatment Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Neuroblastoma Treatment Drugs companies in 2022 (%)
The global Neuroblastoma Treatment Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Cyclophosphamide Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Neuroblastoma Treatment Drugs include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neuroblastoma Treatment Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuroblastoma Treatment Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neuroblastoma Treatment Drugs Market Segment Percentages, by Type, 2022 (%)
Cyclophosphamide
Dinutuximab
Naxitamab
Doxorubicin Hydrochloride
Vincristine Sulfate
Other
Global Neuroblastoma Treatment Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neuroblastoma Treatment Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Other
Global Neuroblastoma Treatment Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Neuroblastoma Treatment Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuroblastoma Treatment Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Neuroblastoma Treatment Drugs revenues share in global market, 2022 (%)
Key companies Neuroblastoma Treatment Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Neuroblastoma Treatment Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neuroblastoma Treatment Drugs, market overview.
Chapter 2: Global Neuroblastoma Treatment Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Neuroblastoma Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neuroblastoma Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neuroblastoma Treatment Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neuroblastoma Treatment Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neuroblastoma Treatment Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neuroblastoma Treatment Drugs Overall Market Size
2.1 Global Neuroblastoma Treatment Drugs Market Size: 2022 VS 2029
2.2 Global Neuroblastoma Treatment Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Neuroblastoma Treatment Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Neuroblastoma Treatment Drugs Players in Global Market
3.2 Top Global Neuroblastoma Treatment Drugs Companies Ranked by Revenue
3.3 Global Neuroblastoma Treatment Drugs Revenue by Companies
3.4 Global Neuroblastoma Treatment Drugs Sales by Companies
3.5 Global Neuroblastoma Treatment Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Neuroblastoma Treatment Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Neuroblastoma Treatment Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neuroblastoma Treatment Drugs Players in Global Market
3.8.1 List of Global Tier 1 Neuroblastoma Treatment Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Neuroblastoma Treatment Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Neuroblastoma Treatment Drugs Market Size Markets, 2022 & 2029
4.1.2 Cyclophosphamide
4.1.3 Dinutuximab
4.1.4 Naxitamab
4.1.5 Doxorubicin Hydrochloride
4.1.6 Vincristine Sulfate
4.1.7 Other
4.2 By Type - Global Neuroblastoma Treatment Drugs Revenue & Forecasts
4.2.1 By Type - Global Neuroblastoma Treatment Drugs Revenue, 2018-2023
4.2.2 By Type - Global Neuroblastoma Treatment Drugs Revenue, 2024-2029
4.2.3 By Type - Global Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Neuroblastoma Treatment Drugs Sales & Forecasts
4.3.1 By Type - Global Neuroblastoma Treatment Drugs Sales, 2018-2023
4.3.2 By Type - Global Neuroblastoma Treatment Drugs Sales, 2024-2029
4.3.3 By Type - Global Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Neuroblastoma Treatment Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neuroblastoma Treatment Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application - Global Neuroblastoma Treatment Drugs Revenue & Forecasts
5.2.1 By Application - Global Neuroblastoma Treatment Drugs Revenue, 2018-2023
5.2.2 By Application - Global Neuroblastoma Treatment Drugs Revenue, 2024-2029
5.2.3 By Application - Global Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Neuroblastoma Treatment Drugs Sales & Forecasts
5.3.1 By Application - Global Neuroblastoma Treatment Drugs Sales, 2018-2023
5.3.2 By Application - Global Neuroblastoma Treatment Drugs Sales, 2024-2029
5.3.3 By Application - Global Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Neuroblastoma Treatment Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Neuroblastoma Treatment Drugs Market Size, 2022 & 2029
6.2 By Region - Global Neuroblastoma Treatment Drugs Revenue & Forecasts
6.2.1 By Region - Global Neuroblastoma Treatment Drugs Revenue, 2018-2023
6.2.2 By Region - Global Neuroblastoma Treatment Drugs Revenue, 2024-2029
6.2.3 By Region - Global Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Neuroblastoma Treatment Drugs Sales & Forecasts
6.3.1 By Region - Global Neuroblastoma Treatment Drugs Sales, 2018-2023
6.3.2 By Region - Global Neuroblastoma Treatment Drugs Sales, 2024-2029
6.3.3 By Region - Global Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Neuroblastoma Treatment Drugs Revenue, 2018-2029
6.4.2 By Country - North America Neuroblastoma Treatment Drugs Sales, 2018-2029
6.4.3 US Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.4.4 Canada Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.4.5 Mexico Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Neuroblastoma Treatment Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Neuroblastoma Treatment Drugs Sales, 2018-2029
6.5.3 Germany Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.5.4 France Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.5.5 U.K. Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.5.6 Italy Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.5.7 Russia Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.5.9 Benelux Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Neuroblastoma Treatment Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Neuroblastoma Treatment Drugs Sales, 2018-2029
6.6.3 China Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.6.4 Japan Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.6.5 South Korea Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.6.7 India Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Neuroblastoma Treatment Drugs Revenue, 2018-2029
6.7.2 By Country - South America Neuroblastoma Treatment Drugs Sales, 2018-2029
6.7.3 Brazil Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.7.4 Argentina Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Neuroblastoma Treatment Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Neuroblastoma Treatment Drugs Sales, 2018-2029
6.8.3 Turkey Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.8.4 Israel Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Neuroblastoma Treatment Drugs Market Size, 2018-2029
6.8.6 UAE Neuroblastoma Treatment Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 United Therapeutics
7.1.1 United Therapeutics Company Summary
7.1.2 United Therapeutics Business Overview
7.1.3 United Therapeutics Neuroblastoma Treatment Drugs Major Product Offerings
7.1.4 United Therapeutics Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.1.5 United Therapeutics Key News & Latest Developments
7.2 Y-mAbs Therapeutics
7.2.1 Y-mAbs Therapeutics Company Summary
7.2.2 Y-mAbs Therapeutics Business Overview
7.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Major Product Offerings
7.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Y-mAbs Therapeutics Key News & Latest Developments
7.3 EUSA Pharma
7.3.1 EUSA Pharma Company Summary
7.3.2 EUSA Pharma Business Overview
7.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Major Product Offerings
7.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.3.5 EUSA Pharma Key News & Latest Developments
7.4 ANI Pharmaceuticals
7.4.1 ANI Pharmaceuticals Company Summary
7.4.2 ANI Pharmaceuticals Business Overview
7.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Major Product Offerings
7.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.4.5 ANI Pharmaceuticals Key News & Latest Developments
7.5 Baxter Healthcare
7.5.1 Baxter Healthcare Company Summary
7.5.2 Baxter Healthcare Business Overview
7.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Major Product Offerings
7.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Baxter Healthcare Key News & Latest Developments
7.6 Ingenus Pharmaceuticals
7.6.1 Ingenus Pharmaceuticals Company Summary
7.6.2 Ingenus Pharmaceuticals Business Overview
7.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Major Product Offerings
7.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Ingenus Pharmaceuticals Key News & Latest Developments
7.7 Pfizer
7.7.1 Pfizer Company Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Neuroblastoma Treatment Drugs Major Product Offerings
7.7.4 Pfizer Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Pfizer Key News & Latest Developments
7.8 Hikma Pharmaceuticals
7.8.1 Hikma Pharmaceuticals Company Summary
7.8.2 Hikma Pharmaceuticals Business Overview
7.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Major Product Offerings
7.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Hikma Pharmaceuticals Key News & Latest Developments
7.9 Teva Pharmaceuticals
7.9.1 Teva Pharmaceuticals Company Summary
7.9.2 Teva Pharmaceuticals Business Overview
7.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Major Product Offerings
7.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Teva Pharmaceuticals Key News & Latest Developments
8 Global Neuroblastoma Treatment Drugs Production Capacity, Analysis
8.1 Global Neuroblastoma Treatment Drugs Production Capacity, 2018-2029
8.2 Neuroblastoma Treatment Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Neuroblastoma Treatment Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neuroblastoma Treatment Drugs Supply Chain Analysis
10.1 Neuroblastoma Treatment Drugs Industry Value Chain
10.2 Neuroblastoma Treatment Drugs Upstream Market
10.3 Neuroblastoma Treatment Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neuroblastoma Treatment Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Neuroblastoma Treatment Drugs in Global Market
Table 2. Top Neuroblastoma Treatment Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Neuroblastoma Treatment Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Neuroblastoma Treatment Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Neuroblastoma Treatment Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Neuroblastoma Treatment Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Neuroblastoma Treatment Drugs Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Neuroblastoma Treatment Drugs Product Type
Table 9. List of Global Tier 1 Neuroblastoma Treatment Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuroblastoma Treatment Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Neuroblastoma Treatment Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Neuroblastoma Treatment Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Neuroblastoma Treatment Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Neuroblastoma Treatment Drugs Sales (K Units), 2024-2029
Table 16. By Application ? Global Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Neuroblastoma Treatment Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Neuroblastoma Treatment Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Neuroblastoma Treatment Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Neuroblastoma Treatment Drugs Sales (K Units), 2024-2029
Table 21. By Region ? Global Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Neuroblastoma Treatment Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Neuroblastoma Treatment Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Neuroblastoma Treatment Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Neuroblastoma Treatment Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Neuroblastoma Treatment Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Neuroblastoma Treatment Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Neuroblastoma Treatment Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Neuroblastoma Treatment Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Neuroblastoma Treatment Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Neuroblastoma Treatment Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Neuroblastoma Treatment Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Neuroblastoma Treatment Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Neuroblastoma Treatment Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Neuroblastoma Treatment Drugs Sales, (K Units), 2024-2029
Table 46. United Therapeutics Company Summary
Table 47. United Therapeutics Neuroblastoma Treatment Drugs Product Offerings
Table 48. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. United Therapeutics Key News & Latest Developments
Table 50. Y-mAbs Therapeutics Company Summary
Table 51. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Offerings
Table 52. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Y-mAbs Therapeutics Key News & Latest Developments
Table 54. EUSA Pharma Company Summary
Table 55. EUSA Pharma Neuroblastoma Treatment Drugs Product Offerings
Table 56. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. EUSA Pharma Key News & Latest Developments
Table 58. ANI Pharmaceuticals Company Summary
Table 59. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Offerings
Table 60. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. ANI Pharmaceuticals Key News & Latest Developments
Table 62. Baxter Healthcare Company Summary
Table 63. Baxter Healthcare Neuroblastoma Treatment Drugs Product Offerings
Table 64. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Baxter Healthcare Key News & Latest Developments
Table 66. Ingenus Pharmaceuticals Company Summary
Table 67. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Offerings
Table 68. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Ingenus Pharmaceuticals Key News & Latest Developments
Table 70. Pfizer Company Summary
Table 71. Pfizer Neuroblastoma Treatment Drugs Product Offerings
Table 72. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Pfizer Key News & Latest Developments
Table 74. Hikma Pharmaceuticals Company Summary
Table 75. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Offerings
Table 76. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Hikma Pharmaceuticals Key News & Latest Developments
Table 78. Teva Pharmaceuticals Company Summary
Table 79. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Offerings
Table 80. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Teva Pharmaceuticals Key News & Latest Developments
Table 82. Neuroblastoma Treatment Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 83. Global Neuroblastoma Treatment Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 84. Global Neuroblastoma Treatment Drugs Production by Region, 2018-2023 (K Units)
Table 85. Global Neuroblastoma Treatment Drugs Production by Region, 2024-2029 (K Units)
Table 86. Neuroblastoma Treatment Drugs Market Opportunities & Trends in Global Market
Table 87. Neuroblastoma Treatment Drugs Market Drivers in Global Market
Table 88. Neuroblastoma Treatment Drugs Market Restraints in Global Market
Table 89. Neuroblastoma Treatment Drugs Raw Materials
Table 90. Neuroblastoma Treatment Drugs Raw Materials Suppliers in Global Market
Table 91. Typical Neuroblastoma Treatment Drugs Downstream
Table 92. Neuroblastoma Treatment Drugs Downstream Clients in Global Market
Table 93. Neuroblastoma Treatment Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Neuroblastoma Treatment Drugs Segment by Type in 2022
Figure 2. Neuroblastoma Treatment Drugs Segment by Application in 2022
Figure 3. Global Neuroblastoma Treatment Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Neuroblastoma Treatment Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Neuroblastoma Treatment Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Neuroblastoma Treatment Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Neuroblastoma Treatment Drugs Revenue in 2022
Figure 9. By Type - Global Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Neuroblastoma Treatment Drugs Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Neuroblastoma Treatment Drugs Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Neuroblastoma Treatment Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 23. US Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 28. Germany Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 37. China Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Neuroblastoma Treatment Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Neuroblastoma Treatment Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Neuroblastoma Treatment Drugs by Region, 2022 VS 2029
Figure 54. Neuroblastoma Treatment Drugs Industry Value Chain
Figure 55. Marketing Channels
